Crinetics Pharmaceuticals, Inc. (CRNX) has a negative trailing P/E of -8.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 41.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -12.41%, forward earnings yield 2.40%. PEG 0.10 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 57/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -56.5 | 0.00 | -54.83 | 577.51 | - |
| 2017 | -37.1 | -0.69 | -22.64 | 166.33 | - |
| 2018 | -13.4 | -0.06 | -8.39 | 149.97 | - |
| 2019 | -12.2 | 1.52 | 5.18 | 508.42 | - |
| 2020 | -5.8 | -0.32 | 2.54 | 6,051.00 | - |
| 2021 | -10.1 | -0.65 | 3.29 | 1,012.96 | - |
| 2022 | -5.8 | -0.46 | 3.01 | 200.82 | - |
| 2023 | -9.6 | -0.56 | 3.83 | 514.87 | - |
| 2024 | -13.8 | 0.00 | 3.12 | 3,975.39 | - |
| 2025 | -9.4 | -0.28 | 4.41 | 568.91 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.43 | $589K | $-6.02M | -1021.9% |
| 2017 | $-0.66 | $2.05M | $-9.16M | -447.8% |
| 2018 | $-2.23 | $2.43M | $-27.12M | -1116.8% |
| 2019 | $-2.05 | $1.19M | $-49.54M | -4152.1% |
| 2020 | $-2.39 | $71K | $-72.86M | -102625.4% |
| 2021 | $-2.78 | $1.08M | $-106.72M | -9899.7% |
| 2022 | $-3.08 | $4.74M | $-159.95M | -3376.7% |
| 2023 | $-3.69 | $4.01M | $-214.53M | -5345.9% |
| 2024 | $-3.69 | $1.04M | $-298.41M | -28720.7% |
| 2025 | $-4.95 | $7.7M | $-465.32M | -6046.2% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-4.77 | $-5.77 – $-2.77 | $62.05M | $57.59M – $66.76M | 10 |
| 2027 | $-4.13 | $-5.38 – $-2.83 | $176.15M | $138.04M – $221M | 9 |
| 2028 | $-2.47 | $-3.72 – $-0.99 | $418.19M | $418.19M – $418.19M | 5 |
| 2029 | $0.95 | $0.67 – $1.22 | $933.07M | $717.14M – $1.14B | 1 |
| 2030 | $4.93 | $3.45 – $6.33 | $1.59B | $1.23B – $1.94B | 1 |
